SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
17695487
Source:
http://linkedlifedata.com/resource/pubmed/id/17695487
Search
Subject
(
60
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0013216
,
umls-concept:C0205179
,
umls-concept:C0205453
,
umls-concept:C0205969
,
umls-concept:C0206135
,
umls-concept:C0701185
,
umls-concept:C0868928
,
umls-concept:C0936012
pubmed:issue
4C
pubmed:dateCreated
2007-8-15
pubmed:abstractText
Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and the efficacy of second line chemotherapy has not been established either.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/8102988
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin
,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin
,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin
,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide
,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin
,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed-author:HatayamaOrieO
,
pubmed-author:KandaShintaroS
,
pubmed-author:KoizumiTomonobuT
,
pubmed-author:KomatsuYoshimichiY
,
pubmed-author:KuboKeishiK
,
pubmed-author:OkadaMitsuyoM
,
pubmed-author:SasabayashiMariM
,
pubmed-author:TakamizawaAkemiA
,
pubmed-author:TsushimaKenjiK
,
pubmed-author:UrushihataKazuhisaK
,
pubmed-author:YasuoMasanoriM
,
pubmed-author:YoshikawaSumikoS
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3005-8
pubmed:meshHeading
pubmed-meshheading:17695487-Adult
,
pubmed-meshheading:17695487-Aged
,
pubmed-meshheading:17695487-Antineoplastic Combined Chemotherapy Protocols
,
pubmed-meshheading:17695487-Camptothecin
,
pubmed-meshheading:17695487-Carboplatin
,
pubmed-meshheading:17695487-Cisplatin
,
pubmed-meshheading:17695487-Cyclophosphamide
,
pubmed-meshheading:17695487-Doxorubicin
,
pubmed-meshheading:17695487-Female
,
pubmed-meshheading:17695487-Humans
,
pubmed-meshheading:17695487-Male
,
pubmed-meshheading:17695487-Middle Aged
,
pubmed-meshheading:17695487-Retrospective Studies
,
pubmed-meshheading:17695487-Survival Rate
,
pubmed-meshheading:17695487-Thymus Neoplasms
,
pubmed-meshheading:17695487-Vincristine
pubmed:articleTitle
Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.
pubmed:affiliation
First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Asahi Matsumoto, Japan.
pubmed:publicationType
Journal Article